Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy effects on the infant

Drug Safety

Volumn 28, Issue 7, 2005, Pages 565-581

  Nordeng, Hedvig ^a   Spigset, Olav ^b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; DESIPRAMINE; DIPHENHYDRAMINE; FLUOXETINE; FLUVOXAMINE; METHADONE; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE;

AGITATION; ANXIETY DISORDER; APNEA; BEHAVIOR; BIRTH WEIGHT; BRADYCARDIA; BRAIN HEMORRHAGE; BREATHING DISORDER; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONVULSION; DEPRESSION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FEEDING DISORDER; FETUS GROWTH; GESTATIONAL AGE; HEART ARRHYTHMIA; HUMAN; HYPERREFLEXIA; HYPOGLYCEMIA; INSOMNIA; IRRITABILITY; JAUNDICE; LETHARGY; MEDICAL LITERATURE; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NECROTIZING ENTEROCOLITIS; NERVOUSNESS; NEWBORN DISEASE; NYSTAGMUS; PETECHIA; PRACTICE GUIDELINE; PREMATURE LABOR; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; RESPIRATORY DISTRESS; REVIEW; RISK BENEFIT ANALYSIS; SEROTONINERGIC SYSTEM; SLEEP DISORDER; SUBARACHNOID HEMORRHAGE; TACHYCARDIA; THIRD TRIMESTER PREGNANCY; TREMOR; WITHDRAWAL SYNDROME;

FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 22344455377     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528070-00002     Document Type: Review

References (74)

1. O'Hara MW. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986; 43: 569-73
2. Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323: 257-60
3. Josefsson A, Berg G, Nordin C, et al. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001; 80: 251-5
4. Johanson R, Chapman G, Murray D, et al. The North Staffordshire Maternity Hospital prospective study of pregnancy-associated depression. J Psychosom Obstet Gynaecol 2000; 21: 93-7
5. Zuckerman B, Bauchner H, Parker S, et al. Maternal depressive symptoms during pregnancy, and newborn irritability. J Dev Behav Pediatr 1990; 11: 190-4
6. Steer RA, Scholl TO, Hediger ML, et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992; 45: 1093-9
7. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome: review of the literature and preliminary findings. Epidemiol Rev 1995; 17: 165-71
8. Lundy B, Jones N, Field T, et al. Prenatal depression effects on neonates. Infant Behav Dev 1999; 22: 121-37
9. Chung TK, Lau TK, Yip AS, et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001; 63: 830-4
10. Orr ST, James SA, Blackmore Prince C. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol 2002; 156: 797-802
11. Jesse DE, Seaver W, Wallace DC. Maternal psychosocial risks predict preterm birth in a group of women from Appalachia. Midwifery 2003; 19: 191-202
12. Tough SC, Newburn-Cook CV, White DE, et al. Do maternal characteristics and past pregnancy experiences predict preterm delivery among women aged 20 to 34? J Obstet Gynaecol Can 2003; 25: 656-66
13. Andersson L, Sundström-Poromaa I, Wulff M, et al. Neonatal outcome following maternal antenatal depression and anxiety: a population-based study. Am J Epidemiol 2004; 159: 872-81
14. Hedegaard M, Henriksen TB, Sabroe S, et al. The relationship between psychological distress during pregnancy and birth weight for gestational age. Acta Obstet Gynecol Scand 1996; 75: 32-9
15. Jacobsen G, Schei B, Hoffman HJ. Psychosocial factors and small-for-gestational-age infants among parous Scandinavian women. Acta Obstet Gynecol Scand Suppl 1997; 165: 14-8
16. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001; 26: 44-8
17. American Academy of Pediatrics Committee on Drugs. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics 2000; 105: 880-7
18. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-8
19. Chambers C, Johnson K, Dick L, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-5
20. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-62
21. Kulin N, Pastuszak A, Sage S, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998; 279: 609-10
22. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry 1997; 171: 391-2
23. Gerola O, Fiocchi S, Rondini G. Antidepressant therapy in pregnancy: a review from the literature and report of a suspected paroxetine withdrawal syndrome in a newborn [in Italian]. Riv Ital Pediatr 1999; 25: 216-8
24. Nijhuis IJ, Kok-Van Rooij GW, Bosschaart AN. Withdrawal reactions of a premature neonate after maternal use of paroxetine [letter]. Arch Dis Child Fetal Neonatal Ed 2001; 84: F77
25. Bhatt J, Coombs RC. Feeding difficulty in a term neonate due to paroxetine withdrawal. Arch Dis Child Online 2001 Jan 3
26. Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90: 288-91
27. Stiskal JA, Kulin N, Koren G, et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001; 84: F134-5
28. Jaiswal S, Coombs RC, Isbister GK. Paroxetine withdrawal in a neonate with historical and laboratory confirmation. Epub 2003 Aug 07. Eur J Pediatr 2003; 162: 723-4
29. Herbst F, Gortner L. Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy? [in German]. Z Geburtshilfe Neonatol 2003; 207: 232-4
30. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993; 92: 721-2
31. Kristensen JH, Ilett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999; 48: 521-7
32. Mohan CG, Moore JJ. Fluoxetine toxicity in a preterm infant. J Perinatol 2000; 20: 445-6
33. Abebe-Campino G, Offer D, Stahl B, et al. Cardiac arrhythmia in a newborn infant associated with fluoxetine use during pregnancy. Ann Pharmacother 2002; 36: 533-4
34. Kent LS, Laidlaw JD. Suspected congenital sertraline dependence. Br J Psychiatry 1995; 167: 412-3
35. Oca MJ, Donn SM. Association of maternal sertraline (Zoloft) therapy and transient neonatal nystagmus. J Perinatol 1999; 19: 460-1
36. Wilson JF. Survey of reference ranges and clinical measurements for psychoactive drugs in serum. Ther Drug Monit 2003; 25: 243-7
37. Australian Adverse Drug Reactions Advisory Committee. Maternal SSRI use and neonatal effects. In: Australian Adverse Drug Reactions Bulletin 2003; 22: 14
38. Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. Am J Psychiatry 2003; 160: 993-6
39. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60: 720-6
40. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73: 330-7
41. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995; 15: 417-20
42. Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48: 996-1000
43. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156: 1129-32
44. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055-61
45. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188: 812-5
46. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72: 184-91
47. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142: 402-8
48. Källen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312-6
49. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113: 368-75
50. Oberlander TF, Eckstein Grunau R, Fitzgerald C, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002; 51: 443-53
51. Isbister GK, Dawson A, Whyte IM, et al. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001; 85: F147-8
52. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42: 757-63
53. Hergovich N, Aigner A, Eichler HG, et al. Paroxetine decreases platelet storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435-42
54. Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10: 35-8
55. Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly people: retrospective cohort study. BMJ 2001; 323: 655-8
56. Stanford MS, Patton JH. In utero exposure to fluoxetine HCl increases hematoma frequency at birth. Pharmacol Biochem Behav 1993; 45: 959-62
57. Mhanna MJ, Bennet II JB, Izatt SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 1997; 100: 158-9
58. Paroxetine. In: Canadian Adverse Drug Reaction Newsletter 1997; 7: 953-4
59. Duijvestijn YC, Kalmeijer MD, Passier AL, et al. Neonatal intraventricular haemorrhage associated with maternal use of paroxetine. Br J Clin Pharmacol 2003; 56: 581-2
60. Salvia-Roiges MD, Garcia L, Gonce-Mellgren A, et al. Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine [in Spanish]. Rev Neurol 2003; 36: 724-6
61. Kliegman RM. Intracranial (intraventricular) hemorrhage. In: Behrman RE, Kliegman RM, Arvin AM, editors. Textbook of pediatrics. 15th ed. Philadelphia (PA): Saunders, 1996: 466-7
62. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159: 1889-95
63. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997; 58 Suppl. 7: 17-21
64. Hostetter A, Stowe ZN, Strader Jr JR, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11: 51-7
65. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants: a pragmatic evaluation of its efficacy. Clin Pediatr 1975; 14: 592-4
66. American Academy of Pediatrics, Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1998; 101: 1079-88
67. Koren G. Discontinuation syndrome following late pregnancy exposure to antidepressants. Arch Pediatr Adolesc Med 2004; 158: 307-8
68. Dodd S, Buist A, Norman TR. Antidepressants and breast-feeding: a review of the literature. Paediatr Drugs 2000; 2: 183-92
69. Misri S, Kostaras X. Benefits and risks to mother and infant of drug treatment for postnatal depression. Drug Saf 2002; 25: 903-11
70. Newport DJ, Hostetter A, Arnold A, et al. The treatment of postpartum depression: minimizing infant exposures. J Clin Psychiatry 2002; 63 Suppl. 7: 31-44
71. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282: 1264-9
72. Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am 2003; 26: 547-62
73. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365: 482-7
74. Ruchkin V, Martin A. SSRIs and the developing brain. Lancet 2005; 365: 451-3